- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00497094
Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis
Stenting vs. Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis - a Randomized Controlled Trial
Background. Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA). The reported rates of neurological complications of CAS substantially decreased during the past years, and the routine use of cerebral protection devices and low profile catheter systems have further increased the procedure´s safety. In the early 90's large surgical trials in North America and Europe (NASCET, ECST and ACAS) demonstrated superiority of CEA compared to best medical treatment for symptomatic and asymptomatic patients. Provided that the ongoing randomized controlled trials comparing CAS and CEA confirm equivalence between the these methods, CAS similar to CEA is applicable to symptomatic and asymptomatic patients with high grade carotid stenosis. However, particularly in asymptomatic patients, the indication for revascularisation remains debatable. Protected CAS is associated with a very low rate of neurological complications, which are below the AHA recommendation for treating asymptomatic patients (3%). However, the introduction of new vascular protective medications like statins and clopidogrel during the recent years substantially improved the spectrum of best medical treatment, and the findings of NASCET, ECST and ACAS with respect to best medical treatment may therefore not be applicable any more.
Study hypothesis and aims. Given the low frequency of spontaneous neurological complications, the preferable therapeutic approach to patients with asymptomatic high grade ( > 80%) carotid artery stenoses is currently unknown. Modern best medical treatment may manage to stabilize the atherosclerotic plaque, while CAS has the potential of resolving the carotid stenosis. Comparative data, however, are not available as yet. We hypothesized that protected CAS has a beneficial effect on occurrence of ipsilateral neurological complications and major adverse cardiac events in high-risk patients with asymptomatic > 80% internal carotid artery stenosis. Therefore, the aim of the present randomized controlled trial was to analyze neurological and cardiovascular outcome of patients treated with elective CAS plus best medical treatment compared to best medical treatment only.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA). The reported rates of neurological complications of CAS substantially decreased during the past years, and the routine use of cerebral protection devices and low profile catheter systems have further increased the procedure´s safety. In the early 90ies large surgical trials in North America and Europe (NASCET, ECST and ACAS) demonstrated superiority of CEA compared to best medical treatment for symptomatic and asymptomatic patients. Provided that the ongoing randomized controlled trials comparing CAS and CEA confirm equivalence between the these methods, CAS similar to CEA is applicable to symptomatic and asymptomatic patients with high grade carotid stenosis. However, particularly in asymptomatic patients, the indication for revascularisation remains debatable. Protected CAS is associated with a very low rate of neurological complications, which are below the AHA recommendation for treating asymptomatic patients (3%). However, the introduction of new vascular protective medications like statins and clopidogrel during the recent years substantially improved the spectrum of best medical treatment, and the findings of NASCET, ECST and ACAS with respect to best medical treatment may therefore not be applicable any more.
Given the low frequency of spontaneous neurological complications, the preferable therapeutic approach to patients with asymptomatic high grade ( > 80%) carotid artery stenoses is currently unknown. Modern best medical treatment may manage to stabilize the atherosclerotic plaque, while CAS has the potential of resolving the carotid stenosis. Comparative data, however, are not available as yet. We hypothesized that protected CAS has a beneficial effect on occurrence of ipsilateral neurological complications and major adverse cardiac events in high-risk patients with asymptomatic > 80% internal carotid artery stenosis. Therefore, the aim of the present randomized controlled trial was to analyze neurological and cardiovascular outcome of patients treated with elective CAS plus best medical treatment compared to best medical treatment only.
SYNOPSIS
BACKGROUND:
The preferable treatment - whether revascularization or conservative - of asymptomatic high-risk patients with > 80% internal carotid artery stenosis (NASCET criteria) is currently unknown.
STUDY HYPOTHESIS:
We hypothesized that protected carotid artery stenting (CAS) plus best medical treatment is associated with reduced rates of ipsilateral neurological complications and major adverse cardiac events in high-risk patients with asymptomatic > 80% internal carotid artery stenosis compared to best medical treatment only.
STUDY DESIGN:
The study is designed as a randomized controlled trial with 1:1 random assignment between two treatment modalities including 300 patients within an scheduled inclusion period of 18 months. The primary and secondary study endpoints are evaluated for an initial two year follow-up period after randomization. Secondary follow-up will be performed for 1, 1.5, 3, 5 and 10 years post randomization.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria
- General Hospital of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Atherosclerosis is the underlying disease
- Patients with an asymptomatic stenosis >80% (NASCET) with a documented progression of the degree of stenosis to >80% within 6 months with a very tight stenosis ≥90% at initial presentation with a >80% stenosis plus silent ipsilateral ischemia documented by CCT or MRI with ipsilateral >80% stenosis plus contralateral >80% stenosis or occlusion with >80% stenosis plus planned major surgery
- Neurologist´s explicit consent to potentially perform CAS
Exclusion Criteria:
- Inability to provide informed consent
- Underlying disease other than atherosclerosis (inflammatory or autoimmune disease)
- Traumatic or spontaneous carotid dissections
- Life expectancy <6 months
- Advanced dementia
- Advanced renal failure (serum creatinine >2.5 mg/dL)
- Unstable severe cardiovascular comorbidities (e.g. unstable angina, heart failure)
- Restenosis after prior CAS or CEA
- Allergy or contraindications to study medications (clopidogrel, statins, ASA)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily).
Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
Additionally patients will undergo carotid artery stenting using a filter wire protection device.
|
Using retrograde transfemoral access an overview aortic angiogram is established.
A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery.
The stenosis is then crossed with a Filter wire.
For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used.
Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure.
Finally a control angiogram is performed to ensure correct placement of the stent.
After successful completion of the procedure, the arterial access site is closed using a standard closure device.
|
No Intervention: 2
Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily).
Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary study endpoints: neurological events (ipsilateral and contralateral), major adverse cardiovascular events (MACE: composite of myocardial infarction, stroke and cardiovascular death) and any death
Time Frame: 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
in-stent restenosis after CAS, neuropsychological function, patient satisfaction, quality of life during follow up.
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin Schillinger, Prof. Dr., General Hospital of Vienna
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 471/2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asymptomatic
-
University of NottinghamCompletedAsymptomatic ConditionsUnited Kingdom
-
Mahidol UniversityRecruitingColonization, AsymptomaticThailand
-
Center for Innovation and Research OrganizationCompletedColonization, AsymptomaticUnited States
-
Taichung Veterans General HospitalCompleted
-
Tel Hai CollegeCompleted
-
Mary K HaydenRush University Medical Center; RML Specialty HospitalRecruitingColonization, Asymptomatic | Candida Auris InfectionUnited States
-
Erasmus Medical CenterUniversity of Calgary; Institute of Tropical Medicine; Indonesia University; Utrecht... and other collaboratorsNot yet recruitingImpact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in Indonesia (COINCIDE)Antimicrobial Resistance | Colonization, Asymptomatic | Colistin | Mcr-1Indonesia
-
University of PrimorskaElettra Synchrotron TriesteCompletedAsymptomatic ConditionSlovenia
-
Centro Universitario La SalleCompleted
-
University of LisbonCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.CompletedAsymptomatic ConditionPortugal
Clinical Trials on carotid artery stenting
-
Jagiellonian UniversityTerminatedStroke, Ischemic | Carotid Atherosclerosis | Carotid Artery Stenosis
-
Kinepict Health Ltd.Semmelweis University; Bács-Kiskun County Teaching HospitalRecruitingCarotid Artery DiseasesHungary
-
Xuanwu Hospital, BeijingShanghai Zhongshan Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaboratorsUnknownCarotid StenosisChina
-
University of PecsCompletedCarotid Stenosis | Ischemia Reperfusion InjuryHungary
-
Providence Health & ServicesCompleted
-
Universität des SaarlandesUnknownCarotid Artery StenosisGermany
-
Xuanwu Hospital, BeijingPeking University Third Hospital; The First Affiliated Hospital of Soochow... and other collaboratorsCompleted
-
RobocathEuropean Cardiovascular Research CenterCompleted
-
Zhejiang Provincial People's HospitalRecruitingCerebral Small Vessel Diseases | Carotid Artery StenosisChina
-
Invatec S.p.A.CompletedCarotid Artery Disease | Stroke PreventionGermany, Italy, Poland